key: cord-0868825-tp4s9ih2
authors: Shi, Yan-Hong; Huang, Yu-Feng; Wang-Ying, Wang; Yang, Li; Zhou, Hua; Sang, Zhen
title: Analysis on the Current Quality Standards of Chinese Materia Medica Used in COVID-19 Prevention and Treatment
date: 2020-07-09
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.105074
sha: dfc646eed4ed0f91846ce98781f73761700959ea
doc_id: 868825
cord_uid: tp4s9ih2

PURPOSE: Traditional Chinese medicine (TCM) has fully engaged and played an essential role in the prevention and treatment of Coronavirus Disease 2019 (COVID-19). This study compares relevant standards on high-frequent Chinese Materia Medicia (CMM) used in this pandemic aiming at reaching a global consensus and ensuring the use of Chinese medicines safely. METHODS: 141 representative Chinese formulas and Chinese Patent Medicines from the National Protocol and the most of Provincial Protocols for controlling COVID-19 in China have been collected to statistical analyze the composition and characteristics of CMM. Among them, the domestic and international standards of 47 varieties with the frequency usage over 10 times were selected to compare their quality requirements in the mainstream pharmacopeias and international standards. RESULTS: The quality requirements of used CMM for fighting COVID-19 on the terms of overall quality control, marker compounds, and safety indicators showed different patterns in these mainstream pharmacopoeias and international standards. The uniformed and scientific quality standards of CMM were urgently needed to promote global acceptation and trade. CONCLUSIONS: These findings will provide evidence for building unified quality and safety standards that can adapt to the characteristics of CMM and promote international trade, and also will be stated that it is of the highest priority for ISO/TC 249 to formulate high-quality standards that consolidate international consensus to ensure quality and safety of the urgently needed CMM.

Since municipalities directly under the Central Government) have formulated and released regional-specific TCM treatment and prevention protocols based on regional characteristics (the Provincial Protocol) [1, 2] . With the full play of the characteristics and advantages of TCM, integrated Chinese and Western treatment has achieved satisfactory result [3] [4] [5] [6] .

It is widely acknowledged that TCM plays an important role and is one of the merits in the epidemic prevention and control. A press conference held on the effectiveness of TCM in the treatment of COVID-19 cases in Wuhan reported that clinical observation showed that TCM has proven to be effective in the treatment of over 90 % of all confirmed COVID-19 cases on the Chinese mainland, said a TCM official on March 24, 2020. Among these confirmed cases, 74,187 were given TCM products, accounting for 91.5% of the total [7] . It was found that TCM helped to relieve the symptoms, reduce the progression from mild to severe and critical, increase recovery rate, decrease mortality rate, and bring the convalescent to normal body functions [8] [9] [10] [11] . Meanwhile, J o u r n a l P r e -p r o o f we noticed that China has adopted the methods of integrating traditional Chinese medicine with western medicine which led to a better outcome of this pandemic.

As Chinese Materia Medica (CMM) played a key role in this pandemic, its standards on quality and safety are attracting more attentions from the public. ISO/TC 249 has accumulated rich experience in developing international standards on CMM and relevant monographs have been recorded in national pharmacopeias which enable CMM to be used globally. In this study, we aimed at analyzing the above-mentioned standards on CMM to recognize the current challenges in the process of their development.

Protocol of China [1, 2] were selected and the usage frequency of each herbal medicine was counted. There are 47 varieties of CMM with the usage frequency over 10 times.

Their botanical origins, morphological identification, and qualitative identification, quantification of marker compounds, heavy metals and residual pesticides in the following mainstream pharmacopeias and international standards were summarized and 

J o u r n a l P r e -p r o o f

The quality standards of CMM is a key technical link for CMM to break the barriers of international trade and gain access to international markets. Under the framework of the globalization of CMM, with the ultimate goal to gain access to international markets, it is indispensable to promote internationalization of CMM by formulating a scientific, advanced and applicable system for quality standards with international recognition to effectively ensure efficacy and safety of CMM.

The current quality standards of the above selected 47 varieties of CMM in the mainstream pharmacopeias and international standards are shown as follows. [12] [13] [14] [15] [16] [17] All varieties of used CMM have corresponding quality standards in ChP, with more than 85% collected in JP and KP but with fewer description in EP and USP/ USP-HMC for 31.91% and 25.53%, respectively ( Table 2 ). [18, 19] There are 14 varieties included in WHO monographs on selected medicinal plants, and 16 varieties included in ISO international standards. For ISO standards, 2 varieties of CMM, Lonicerae Japonicae Flos and Scutellariae Radix have been officially published, and 14 varieties are under development stage (Table 3) .

The standard of Scutellariae Radix is the only CMM that has been recorded in ChP, JP, 

J o u r n a l P r e -p r o o f Based on the characteristics of CMM, the standards of the mainstream pharmacopoeias and international standards mainly focus on the safety issues of CMM, such as botanical origins, morphological identification, and qualitative identification, quantification of marker compounds, heavy metals and residual pesticides [11] [12] [13] [14] [15] [16] [17] [18] . However, the mainstream pharmacopoeias and international standards have different emphases on standards in terms of overall quality control of CMM, selection of marker compounds, safety issues and others. Taking Scutellariae Radix as an example, the comparative analysis of the standards among the mainstream pharmacopoeias, ISO and other international standards is as follows ( Table 4) :

(1) Apart from the basic contents such as botanical origins, morphological features, microscopic characteristics, qualitative identification, purity test, assay, and storage, etc. (2) Purity test includes moisture and total ash contents, but with differences in limit values of each standard.

(3) The regulations and requirements on safety indicators such as heavy metals and residual pesticides showed a different pattern in these mainstream pharmacopoeias and international standards.

(4) The main differences of the standards are the gaps in the selection of marker compounds and limitation regulation. The single marker compound of baicalin is used for quantitative analysis in ChP, EP, JP, ISO, and WHO standards, while apart from baicalin, multi-marker compounds are referred in KP and USP. 

The outbreak of COVID-19 reminds us that in dealing with major emergencies of global 

In this study, the characteristics of used CMM for prevention and treatment of COVID-19, and the quality requirements of 47 main varieties of CMM in mainstream pharmacopoeias and international standards were comprehensively analyzed and compared. These findings provide evidence for developing harmonized standards which can be relied on to guarantee the safety and quality of CMM. This study also stated that it is of the highest priority for ISO/TC 249 to formulate high-quality standards that can consolidate global consensus and contain the characteristics of CMM at most.

The authors declared that there is no conflict of interest.

We confirmed that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. J o u r n a l P r e -p r o o f 

General Office of the National Health and Health Commission, Office of the State Administration of Traditional Chinese Medicine. Notice on Issuing a New Coronary Virus Pneumonia Diagnosis and Treatment guidelines

Trend book of Diagnosis and Treatment Protocol of Traditional Chinese medicine for COVID-19

COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease

Combination of Western Medicine and Chinese Traditional Patent Medicine in Treating a Family Case of COVID-19 in Wuhan

Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

Traditional Chinese medicine for COVID-19 treatment

The State Council Information Office, The People's Republic of China, TCM treatment effective on over 90% of COVID-19 patients on China's mainland: Official

Efficacy and Safety of Lianhuaqingwen Capsules, a Repurposed Chinese Herb

The Clinical Benefits of Chinese Patent Medicines Against COVID-19 Based on Current Evidence

Treatment Efficacy Analysis of Traditional Chinese Medicine for Novel Coronavirus Pneumonia (COVID-19): An Empirical Study From Wuhan

Traditional Chinese Medicine in the Treatment of Patients Infected With 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective

Chinese Pharmacopoeia, Part 1

Japanese Pharmacopoeia, 17 th ed. Society of Japanese Pharmacopoeia

Korea food and drug administration

The European Pharmacopoeia Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM), European Pharmacopoeia

J o u r n a l P r e -p r o o f